Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937

Bellus Health

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: [14C]-BLU-5937

Study type: Interventional

Funder types: Industry

Identifiers

NCT05244759

BUS-P1-03

Details and patient eligibility

About

This is a single-centre, open-label, non-randomised, single-period, single-dose study in healthy male subjects designed to assess the mass balance recovery, PK, metabolite profile and metabolite identification of [14C]-BLU-5937.

Enrollment: 6 patients

Sex: Male

Ages: 30 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy males

Exclusion criteria

• History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, neurological or psychiatric disorder,as judged by the investigator

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

6 participants in 1 patient group

Arm 1

Experimental group

Description:

Single oral dose of \[14C\]-BLU-5937

Treatment:

Drug: [14C]-BLU-5937